Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 375-382

  Stecklair, Kataleeya P ^a,b   Hamburger, Deborah R ^a,b   Egorin, Merrill J ^a,b   Parise, Robert A ^a,b   Covey, Joseph M ^b,c   Eiseman, Julie L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Collagen type I; Halofuginone; Matrix metalloproteinase; Pharmacokinetics

Indexed keywords

COLLAGEN TYPE 1; GELATINASE A; HALOFUGINONE; NSC 713205;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; BRAIN; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; ERYTHROCYTE; FEMALE; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; SKELETAL MUSCLE; SPECIES DIFFERENCE; SPLEEN; TISSUE DISTRIBUTION; URINARY EXCRETION;

EID: 0034754264     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100367     Document Type: Article

References (40)

1. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis
2. Proteasome inhibitors: A novel class of potent and effective antitumor agents
3. Signal transduction pathway targets for anticancer drug discovery
4. A Bayesian extension of the minimal AIC procedures of autoregressive model fitting
5. An overview of topoisomerase I-targeting agents
6. Telomerase as a possible target for anticancer therapy
7. Cell cycle molecular targets in novel anticancer drug discovery
8. Halofuginone, a specific collagen type I inhibitor, reduces anastomic intimal hyperplasia
9. A program package for simulation and parameter estimation in pharmacokinetic systems
10. Efficacy of Stenerol (halofuginone) III for the control of coccidiosis in turkeys
11. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
12. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone
13. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression
14. The implications of angiogenesis for the biology and therapy of cancer metastasis
15. What is the evidence that tumors are angiogenesis dependent?
16. The role of angiogenesis in tumor growth
17. Inhibition of angiogenesis
18. Anticancer drug targets: Growth factors and growth factor signaling
19. Halofuginone: An inhibitor of collagen type I synthesis
20. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone
21. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
22. Anticancer drug targets: Approaching angiogenesis
23. Pharmacokinetics of halofuginone in cattle
24. The NCI anticancer drug screen: A smart screen to identify effectors of novel targets
25. The effect of halofuginone lactate on experimental Cryptosporidium parvum infections in calves
26. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: A novel inhibitor of collagen type I synthesis
27. Reduction in pulmonary fibrosis in vivo by halofuginone
28. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone
29. Inhibition of collagen synthesis, smooth muscle proliferation, and injury-induced intimal hyperplasia by halofuginone
30. Halofuginone - An inhibitor of collagen type I synthesis - Prevents postoperative formation of abdominal adhesions
31. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: In vivo and in vitro study in a rat model
32. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery
33. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis
34. The effects of halofuginone and salinomycin, alone and in combination, on live performance and skin characteristics of broilers
35. LAGRAN program for area and moments in pharmacokinetic analysis
36. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA
37. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
38. Anticancer drug targets: Cell cycle and checkpoint control
39. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
40. A comparison of numerical integrating algorithms by trapezoidal. LaGrange, and spline approximation